Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrew McConaghie

Senior Writer

Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.

He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.

Set Alert for Articles By Andrew McConaghie

Latest From Andrew McConaghie

After Real-World Data Row, AZ Looks To NHS England For Tagrisso Deal

Tagrisso has become AstraZeneca’s oncology flagship product, but cannot secure frontline use in England.
Commercial United Kingdom

Tecentriq Disappoints In Post-Surgery Bladder Cancer

Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.
Commercial ImmunoOncology

UK Biotech Financing Holds Up Despite Woodford and Brexit

Neil Woodford’s fall from grace and Brexit dragged on an otherwise buoyant sector.

Biologics Commercial

Horizon Sees Blockbuster Future For Tepezza After US Approval

Once a pariah because of its price gouging, the new approval represents a change of tack from Horizon.

Approvals Commercial

Biopharma Leaders Join Trump And Thunberg In Davos

Often dismissed as a meeting of the global elite, Davos is nevertheless a chance for biopharma leaders to take part in ‘big picture’ debates

Business Strategies Commercial

Roche Gears Up For Potential Neuroscience Breakthroughs

Neuroscience could be this decade’s big growth story, but clinical and market access challenges differ to oncology.

Commercial Gene Therapy
See All
UsernamePublicRestriction

Register